What Hims is offering now
Hims & Hers said it will offer five compounded formulations as part of the initial rollout: sermorelin, glutathione, nicotinamide adenine dinucleotide known as NAD+, vitamin B-12, and L-carnitine. Peptides are short chains of amino acids. According to the company, sermorelin is pitched as a growth-hormone stimulator for recovery, body composition, and anti-aging, while glutathione is advertised for anti-aging and athletic recovery, and NAD+ is tied to cellular metabolism.
Vitamin B-12 supports the formation of red blood cells, DNA synthesis, and nerve health, and L-carnitine is said to aid the conversion of fat into usable energy. Some prescription versions of both carry FDA approval for well-recognized indications, chiefly when a deficiency has been diagnosed. Hims says its compounded products are not FDA approved; however, it asserts they are lawful and made in pharmacies that adhere to strict quality requirements and hold state licenses with inspections by state boards of pharmacy.
How Hims says care will work, and what it still does not know
The process begins with a review of each person's medical background and objectives conducted by a licensed clinician trained in peptide therapies, who can customize a plan when appropriate. Hims plans to leverage its messaging platform to follow up and tweak treatment if outcomes lag, and to direct patients to other care when necessary. For the time being, individuals with serious conditions - including cardiovascular, liver, or kidney disease - won't be eligible.
Chief Medical Officer Dr. Anant Vinjamoori noted there are still knowledge gaps, saying, "We don't have all of this data that we're used to having with compounds like this," and that the company aims to lead as evidence develops. Patients can also use Care+, which pairs treatment with twice-a-year lab testing and 24/7 messaging with providers trained in peptide therapy. Board member Andrew Huberman called the compounds "real medical treatments, not just a wellness trend" and said Hims provides safe access through "trusted sourcing and physician oversight."
The caution flags from scientists
Researchers urge caution with unapproved peptides. Tufts chemist Joshua Kritzer said they should be viewed like drugs that have not been rigorously tested, warning that anecdotal reports are not enough to justify use. He added that without large clinical trials, rare but serious complications cannot be ruled out.
Dosing is a major unknown. UC Davis Health professor Paul Knoepfler said "the dosing for these products really has not been established," and warned that excessive amounts of a synthetic peptide could spark harmful immune reactions. He favors more clinician contact and careful review of patient conditions, cancer history, and other medications before use.
When industries overlap, staying informed matters, so sign up for the free Market Briefs newsletter that explains markets in five minutes or less
What the evidence shows
Results vary by compound. In 2026, a systematic review that screened 113 studies found zero eligible clinical outcome trials in humans demonstrating that NAD+ given intravenously or intramuscularly improves anti-aging, energy, or wellness outcomes. A review of 37 L-carnitine trials associated the supplement with about 2.7 pounds of average weight loss, though that does not prove a compounded injection would work the same way.
The predominant medical use of vitamin B-12 injections is treating confirmed deficiency, a condition present in 3.6% of U.S. adults. Evidence for glutathione remains thin; despite heavy promotion of IV injections for skin whitening, they do not have FDA approval.
The policy backdrop and what comes next for Hims
Hims is launching amid a federal shift. That non-enforcement policy does not equal FDA approval. That step came after a 2023 FDA action tightening peptide compounding because of worries about safety, impurities, and immune reactions.
Backing broader access, the Health and Human Services Secretary, Robert F. Kennedy Jr., has described himself as a "big fan" and argued earlier limits pushed Americans toward potentially unsafe overseas products. He has previously described using BPC-157 for a muscle injury. Hims plans to add more peptides made in the U.S. over time, including BPC-157 and TB-500, though most research on both has been in animals. The announcement also follows the company's February 2025 acquisition of a California peptide manufacturing facility with advanced peptide synthesizers.
Because choices about new products can touch finances, subscribe to the free daily Market Briefs for a clear five minute market snapshot
